Photoradiation therapy--clinical and drug advances.
Photoradiation therapy--clinical and drug advances.
复制标题
光放射治疗——临床和药物进展。
DOI：
10.1007/978-1-4684-4406-3_2
复制
发表时间：
1983
影响因子：
--
通讯作者：
K. E. Wityk
中科院分区：
文献类型：
--
作者：
T. Dougherty;D. Boyle;K. R. Weishaupt;B. Henderson;W. Potter;D. Bellnier;K. E. Wityk
使用血卟啉衍生物（HPD 1）作为光敏剂的光辐射疗法（PRT）正被美国和国外的许多小组广泛研究用于各种恶性肿瘤。在Roswell Park，虽然我们报告的大多数数据涉及皮肤和皮下病变的治疗，主要是晚期疾病患者，但我们越来越多地研究PRT治疗其他类型病变。在本卷的其他地方，文森特博士将介绍我们对肺部和气管病变的内镜PRT研究，道格拉斯博士将介绍我们对食管肿瘤的研究。此外，我们还与West博士一起治疗脑瘤，与Shedd、Sako和Raczak博士一起治疗头颈部肿瘤。此外，我们将报告有关HPD活性成分的几项基础研究以及HPD体外摄取和保留研究（亨德森，Bellnier）。
Photoradiation therapy (PRT) using hematoporphyrin derivative (HPD1) as photosensitizer is becoming widely investigated by many groups in the U.S. and abroad for a variety of malignancies. At Roswell Park, while most of our reported data deals with treatment of cutaneous and subcutaneous lesions, largely in patients with advanced disease, we are increasingly investigating PRT for other types of lesions. Elsewhere in this volume, our studies on endoscopic PRT for lung and tracheal lesions will be described by Dr. Vincent, and studies of esophageal tumors by Dr. Douglass. In addition we are carrying out treatment of brain tumors with Dr. West and head and neck tumors with Drs. Shedd, Sako and Raczak. In addition, we will be reporting on several basic studies regarding the active component of HPD as well as uptake and retention studies of HPD in vitro (Henderson, Bellnier).
影响因子：
11.2
作者：
Kessel,D
通讯作者：
Kessel,D